Indaptus Therapeutics Stock Alpha and Beta Analysis
| INDP Stock | USD 1.03 0.01 0.96% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Indaptus Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Indaptus Therapeutics over a specified time horizon. Remember, high Indaptus Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Indaptus Therapeutics' market risk premium analysis include:
Beta 2.72 | Alpha (0.77) | Risk 7.52 | Sharpe Ratio (0.05) | Expected Return (0.40) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Indaptus |
Indaptus Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Indaptus Therapeutics market risk premium is the additional return an investor will receive from holding Indaptus Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Indaptus Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Indaptus Therapeutics' performance over market.| α | -0.77 | β | 2.72 |
Indaptus Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Indaptus Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Indaptus Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Indaptus Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Indaptus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Indaptus Therapeutics shares will generate the highest return on investment. By understating and applying Indaptus Therapeutics stock market price indicators, traders can identify Indaptus Therapeutics position entry and exit signals to maximize returns.
Indaptus Therapeutics Return and Market Media
The median price of Indaptus Therapeutics for the period between Sat, Aug 31, 2024 and Fri, Nov 29, 2024 is 1.24 with a coefficient of variation of 15.77. The daily time series for the period is distributed with a sample standard deviation of 0.21, arithmetic mean of 1.31, and mean deviation of 0.18. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program Company Expands Enrollment of Patients on Weekly Dosing at Two Different ... | 09/05/2024 |
2 | Disposition of 2500 shares by Linscott Walt Addison of Indaptus Therapeutics at 72.0 subject to Rule 16b-3 | 09/23/2024 |
3 | Acquisition by Jeffrey Meckler of 12000 shares of Indaptus Therapeutics at 7.0 subject to Rule 16b-3 | 09/26/2024 |
4 | 12 Health Care Stocks Moving In Fridays Intraday Session - Benzinga | 09/27/2024 |
5 | Acquisition by Jeffrey Meckler of 75000 shares of Indaptus Therapeutics at 1.105 subject to Rule 16b-3 | 10/09/2024 |
6 | Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations | 10/22/2024 |
7 | Indaptus Therapeutics Enters Clinical Supply Agreement with BeiGene for Combination Study | 10/28/2024 |
8 | Acquisition by Michael Newman of 290000 shares of Indaptus Therapeutics at 8.87 subject to Rule 16b-3 | 11/08/2024 |
9 | Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 11/12/2024 |
10 | Indaptus Therapeutics, Inc. Announces 2.135 Million Registered Direct Offering and Concurrent Private Placement | 11/22/2024 |
11 | Acquisition by Jeffrey Meckler of 42553 shares of Indaptus Therapeutics at 1.05 subject to Rule 16b-3 | 11/25/2024 |
About Indaptus Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Indaptus or other stocks. Alpha measures the amount that position in Indaptus Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 8.77 | 7.94 | 5.05 | 9.25 | Net Debt To EBITDA | 5.04 | 0.64 | 0.81 | 0.76 |
Indaptus Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Indaptus Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Indaptus Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Indaptus Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Indaptus Therapeutics. Please utilize our Beneish M Score to check the likelihood of Indaptus Therapeutics' management manipulating its earnings.
| 15th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Indaptus Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.